TEVA-TERIPARATIDE INJECTION 250 MCG — DIN 02486423
TERIPARATIDE (TERIPARATIDE ACETATE) : 250 MCG · TEVA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-TERIPARATIDE INJECTION?
TEVA-TERIPARATIDE INJECTION 250 MCG contains TERIPARATIDE (TERIPARATIDE ACETATE) : 250 MCG. It is listed in the Health Canada Drug Product Database under DIN 02486423, held by TEVA CANADA LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 08-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-TERIPARATIDE INJECTION used for?
TEVA-TERIPARATIDE INJECTION is indicated for the treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who have failed or are intolerant to previous osteoporosis therapy. It is also indicated to increase bone mass in men with primary or hypogonadal severe osteoporosis who have failed or are intolerant to previous osteoporosis therapy. The effects of teriparatide on risk for fracture in men have not been demonstrated. Additionally, it is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women who are at increased risk for fracture. Severe osteoporosis may be confirmed by low bone mass or the presence or history of osteoporotic fracture. Non-vertebral fractures may manifest as back pain, height loss, or kyphosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Teriparatide cost around the world?
Teriparatide is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 6 | 8 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 8 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 4 | 7 | CZK███.██ |
| United States | acquisition | 1 | 7 | USD███.██ |
| Australia | ex-manufacturer | 3 | 6 | AUD███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Saudi Arabia | public | 5 | 6 | SAR███.██ |
| South Africa | single exit price | 3 | 3 | ZAR███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
53 pack listings across 38 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Teriparatide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Teriparatide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Teriparatide, across 4 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 1 | 1 | APO-TERIPARATIDE INJECTION | Sourceable in Canada |
| AVIR PHARMA INC. | 1 | 1 | OSNUVO | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-TERIPARATIDE INJECTION | Sourceable in Canada |
| ELI LILLY CANADA INC | 1 | 0 | FORTEO | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MCG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | TEVA-TERIPARATIDE INJECTION is available in (1) pre-filled pen per carton. Each 2.4 mL prefilled multidose injection pen delivers 20 mcg of TEVA-TERIPARATIDE INJECTION per dose. |
| Storage | The TEVA-TERIPARATIDE INJECTION pen should be stored under refrigeration at 2-8°C at all times. During use, time out of the refrigerator should be minimized; the dose may be delivered immediately following removal from the refrigerator. When stored under refrigerated conditions at 2-8°C, TEVA-TERIPARATIDE INJECTION is stable until the date of expiry. Do not freeze. Do not use if it has been frozen. The pen can be used for up to 28 days including the first injection, if stored properly. After the 28-day use period, discard the pen even if it still contains some unused solution. Do not store the pen with a needle attached as this may cause air bubbles to form in the medicine cartridge. Store the pen with the blue cap on. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Teriparatide |
|---|---|
| ATC code | H05AA02 |
| AHFS class | 84:80.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02486423 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2486423 |
| Brand name | TEVA-TERIPARATIDE INJECTION |
| Generic / active ingredient | TERIPARATIDE (TERIPARATIDE ACETATE) : 250 MCG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | H05AA02 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H05AA |
| Current status | MARKETED |
| Status date | 08-Jul-2020 |
| Original market date | 2020-01-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
TEVA-TERIPARATIDE INJECTION should be administered as a subcutaneous injection into the thigh or abdominal wall. The recommended dosage is 20 mcg once a day. The maximum lifetime exposure to TEVA-TERIPARATIDE INJECTION for an individual patient should generally be 24 months. Use beyond 24 months should only be considered if the patient remains at or has returned to having a high risk for fracture. The initial administration should occur under circumstances where the patient can sit or lie down, in case of orthostatic hypotension. Patients should receive supplemental Calcium and vitamin D if dietary intake is inadequate. TEVA-TERIPARATIDE INJECTION is a clear and colourless solution; do not use if solid particles appear or if the solution is cloudy or coloured. Do not use past the stated expiration date. No data are available on the safety or efficacy of intravenous or intramuscular injection of teriparatide. Patients and caregivers should receive proper training on pen use and read the Pen User Manual. The 2.4 mL prefilled pen is not primed before each dose and can be used for up to 28 days if stored properly. After 28 days, the pen should be discarded even if it contains unused solution. The pen should never be shared.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
TEVA-TERIPARATIDE INJECTION is contraindicated for: Hypersensitivity to teriparatide or any of its excipients. Pre-existing hypercalcemia. Severe renal impairment. Metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and Paget's disease of the bone). Unexplained elevations of alkaline phosphatase. Prior external beam or implant radiation therapy involving the skeleton. Bone metastases or a history of skeletal malignancies. Pregnancy and nursing mothers. Pediatric patients or young adults with open epiphyses.
Warnings and precautions
Carcinogenicity: Two carcinogenicity bioassays in Fischer 344 rats showed that teriparatide injections resulted in increases in bone tumours, including osteosarcoma, in a dose- and duration-dependent manner. Osteosarcoma was not observed in teriparatide clinical trials, but has been reported in a post-market setting. However, observational studies have not shown an increased incidence of osteosarcoma with teriparatide treatment. TEVA-TERIPARATIDE INJECTION should not be prescribed to patients at increased baseline risk for osteosarcoma (e.g., Paget's disease, pediatric and young adult with open epiphyses, history of radiation therapy involving the skeleton). General: The maximum lifetime exposure to TEVA-TERIPARATIDE INJECTION for an individual patient should generally be 24 months. Use beyond 24 months should only be considered if the patient remains at or has returned to having a high risk for fracture. Urolithiasis: The frequency of urolithiasis was similar in clinical trials between teriparatide and placebo. However, teriparatide has not been studied in patients with active urolithiasis. Caution should be exercised in patients with active or recent urolithiasis or pre-existing hypercalciuria due to the potential to exacerbate this condition. Hypotension: Isolated episodes of transient orthostatic hypotension were observed in short-term clinical studies, typically within 4 hours of dosing and resolving within minutes to hours. Patients experiencing symptoms should not drive or operate machinery until asymptomatic. Hypercalcemia: Although symptomatic hypercalcemia was not observed in clinical trials, patients should contact a healthcare provider if they develop persistent symptoms of hypercalcemia (i.e., nausea, vomiting, constipation, lethargy, muscle weakness).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TERIPARATIDE INJECTION | 250 MCG | SOLUTION | APOTEX INC | MARKETED | 02498804 |
| OSNUVO | 250 MCG | SOLUTION | AVIR PHARMA INC. | MARKETED | 02495589 |
| FORTEO | 250 MCG | SOLUTION | ELI LILLY CANADA INC | CANCELLED POST MARKET | 02254689 |
2 · Same class — other molecules in ATC H05AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Teriparatide | APO-TERIPARATIDE INJECTION · FORTEO · OSNUVO · TEVA-TERIPARATIDE INJECTION | 4 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-TERIPARATIDE INJECTION called?
Also recorded in Canada as: Forteo (US), Forsteo (EU), Forsteo (UK), Terrosa (EU), Movymia (EU), Sondelbay (EU), Livogiva (EU), Terifrac (IN), Bondezza (IN), Zortab (IN), Teriparatide Acetate (US), Teriparatide (UK).
The same molecule, Teriparatide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Terrosa | Latin | Australia, Czechia, Saudi Arabia |
| Forteo | Latin | Bahrain, South Africa |
| MOVYMIA | Latin | Czechia |
| Osendea | Latin | Saudi Arabia |
| Ritosa | Latin | Australia |
| Sondelbay | Latin | Czechia, Saudi Arabia |
| Teriparatide Lupin | Latin | Australia |
| FORSTEO | Latin | Czechia |
| TERATYDE | Latin | South Africa |
| Tericresco | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.